Synthesis, in vitro anti-human immunodeficiency virus structure-activity relationships and biological stability of 5'-O-myristoyl analogue derivatives of 3'-azido-2',3'-dideoxythymidine (AZT) as potential prodrugs

Antiviral Chemistry and Chemotherapy

Volumn 9, Issue 4, 1998, Pages 311-323

  Parang, K ^a   Wiebe, L I ^a   Knaus, E E ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

3' azido 2',3' dideoxythymidine; Anti HIV activity; Enzymic hydrolysis; Ester prodrugs; Myristic acid analogues; Structure activity relationships

Indexed keywords

3' AZIDO 2',3' DIDEOXY 5' O (12 BROMODODECANOYL)THYMIDINE; 3' AZIDO 2',3' DIDEOXY 5' O (4 OXATETRADECANOYL)THYMIDINE; 3' AZIDO 2',3' DIDEOXY 5' O [11 (4 IODOPHENOXY)UNDECANOYL]THYMIDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ESTERASE; MYRISTIC ACID; PRODRUG; UNCLASSIFIED DRUG; ZIDOVUDINE; ZIDOVUDINE DERIVATIVE;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG STABILITY; DRUG SYNTHESIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTI-HIV AGENTS; ANTIVIRAL AGENTS; CELL LINE; ESTERASES; ESTERS; HUMANS; MOLECULAR STRUCTURE; MYRISTATES; NUCLEOSIDES; PRODRUGS; RATS; STRUCTURE-ACTIVITY RELATIONSHIP; ZIDOVUDINE;

EID: 0031848324     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Aggarwal SK, Gogu SR, Rangan SRS & Agrawal KC (1990) Synthesis and biological evaluation of prodrugs of zidovudine. Journal of Medicinal Chemistry 33:1505-1510.
2. Balzarini J, Wedgwood O, Kruining J, Pelemans H, Heijtink R, De Clercq E & McGuigan C (1996) Anti-HIV and anti-HBV activity and resistance profile of 2′,3′-dideoxy-3′-thiacytidine (3TC) and its arylphosphoramidate derivative CF 1109. Biochemical and Biophysical Research Communications 225:363-369.
3. Brewster ME, Anderson WR, Helton DO, Bodor N & Pop E (1995) Dose-dependent brain delivery of zidovudine through the use of a zidovudine chemical delivery system. Pharmacological Research 12:796-798.
4. Czernecki S & Valery J-M (1991) An efficient synthesis of 3′-azido-3′-deoxythymidine (AZT). Synthesis:239-240.
5. Heiati H. Tawashi R, Shivers RR & Phillips NC (1997) Solid lipid nanoparticles as drug carriers I. Incorporation and retention of the lipophilic prodrug 3′-azido-3′-deoxythymidine palmitate. International Journal of Pharmaceutics 146:123-131.
6. Horrobin DF, Stewart JCM & Winther MD (1993) Antivirals. US Patent (June 1) 5,216,142. Chemical Abstracts 114: 167714j.
7. Kamijo T, Harada H & lizuka K (1984) An improved and convenient synthesis of esters using 1,1′-carbonyldiimidazole and a reactive halide. Chemistry and Pharmacology Bulletin 32:5044-5047.
8. Kawaguchi T, Ishikawa K, Seki T & Juni K (1990) Ester prodrugs of zidovudine. Journal Pharmceutical Science 79:531-533.
9. Langner CA, Travis JK, Caldwell SJ, Tianbao JE, Li Q, Bryant ML, Devadas B, Gokel GW, Kobayashi GS & Gordon JI (1992) 4-Oxatetradecanoic acid is fungicidal for Cryptococcus neoformans and inhibits replication of human immunodeficiency virus I. Journal of Biological Chemistry 267:17159-17169.
10. Mitsuya H, Weinhold KJ, Furman PA, St Clair MH, Lehrman SN, Gallo RC, Bolognesi D, Barry DW & Broder S (1985) 3′-Azido-3′-deoxythymidine (BWA509U): an antiviral agent that inhibits the infectivity and cytopathic effect on human T-lymphocytropic virus type III/lymphadenopathy-associated virus in vitro. Proceedings of the National Academy of Sciences, USA 82:7096-7100.
11. Paige LA, Zheng G, Shawn AD, Cassady JM & Geahlen RL (1990) Metabolic activation of 2-substituted derivatives of myristic acid to form potent inhibitors of myristoyl CoA:protein N-myristoyltransferase. Biochemistry 29:10566-10573.
12. Parang K, Knaus EE, Wiebe LI, Sardari S, Daneshtalab M & Csizmadia F (1996) Synthesis and antifungal activities of myristic acid analogs. Archives of Pharmacology - Pharmaceutical Medical Chemistry 329:475-482.
13. Parang K, Wiebe LI, Knaus EE, Huang J-S, Tyrrell DL & Csizmadia F. (1997a) In vitro antiviral activities of myristic acid analogs against human immunodeficiency and hepatitis B viruses. Antiviral Research 34:75-90.
14. Parang K, Wiebe LI & Knaus EE (1997b) Syntheses and biological evaluation of 5′-O-myristoyl derivatives of thymidine against human immunodeficiency virus (HIV-1). Antiviral Chemistry and Chemotherapy 8: 417-427.
15. Parang K, Knaus EE & Wiebe LI (1998) Synthesis, in vitro anti-HIV activity, and biological stability of 5′-O-myristoyl analogue derivatives of 3′-fluoro-2′,3′-dideoxythymidine (FLT) as potential prodrugs of FLT Nucleosides & Nucleotides 17:987-1008.
16. Sharma AP, Ollapally AP ′ Lee H (1993) Synthesis and anti-HIV activity of prodrugs of azidothymidine. Antiviral Chemistry and Chemotherapy 4:93-96.
17. Silverman RB (1989) In: The Organic Chemistry of Drug Design and Drug Action, pp. 352-401. New York Academic Press.
18. Torrence PF, Kinjo J, Lesiak K, Balzarini J & De Clercq E (1988) AIDS dementia: synthesis and properties of a derivative of 3′-azido-3′-deoxythymidine (AZT) that may become locked into the central nervous system. FEBS Letters 234: 135-140.
19. Tsuzuki N, Hama T, Kawada M, Haui A, Konishi R, Shiwa S, Ochi Y, Futaki S & Kitagawa K (1994) Adamantane as a brain-directed drug carrier for poorly absorbed drug. 2. AZT derivatives conjugated with the 1-adamantane moiety. Journal of Pharmaceutical Science 83:481-484.
20. Wang Y & Sawchuk RJ (1995) Zidovudine transport in the rabbit brain during intravenous and intracerebroventricular infusion. Journal of Pharmaceutical Science 84:871-876.
21. Weislow OW, Kiser R, Fine D, Bader J, Shoemaker RH & Boyd MR (1989) New soluble formazan assay for HIV-1 cytopathic effects: application to high-flux screening of synthetic and natural products for AIDS-antiviral activity. Journal of the National Cancer Institute 81:577-586.